#1ADM in 686089 Baxter FRONT LINE CARE REAZ RASUL President, Front Line Care 2022 Investor Conference#2Forward-Looking Statements The presentations being made on May 25, 2022 include forward-looking statements concerning Baxter's financial results, R&D pipeline, including planned product launches (many of which are subject to regulatory approval and may require additional investment) and results of clinical trials, business development activities (including anticipated cost and revenue synergies), capital structure, cost savings initiatives, Baxter's long range plan (which includes financial outlook for 2022 and 2022-2025) and other growth strategies. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the impact of global economic conditions (including the ongoing war in Ukraine and the related economic sanctions being imposed globally in response to the conflict and potential trade wars) and public health crises and epidemics, such as the ongoing coronavirus (COVID-19) pandemic, on the company and its employees, customers and suppliers, including foreign governments in countries in which the company operates; demand for and market acceptance of risks for new and existing products; product development risks (including satisfactory clinical performance and obtaining required regulatory approvals); product quality or patient safety concerns; continuity, availability and pricing of acceptable raw materials and component supply (including impacts from COVID-19); inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of a natural disaster, public health crises and epidemics/pandemics, geopolitical crises, regulatory actions or otherwise); accurate identification of and execution on business development and R&D opportunities and realization of anticipated benefits (including the acquisitions of Cheetah Medical, Seprafilm Adhesion Barrier, specified OUS rights to Caelyx/Doxil, full U.S. and specific OUS rights to Transderm Scop, PerClot, Hillrom and certain rights to Zosyn in the U.S. and Canada); breaches or failures of Baxter's information technology systems or products, including by cyberattack, unauthorized access or theft; the adequacy of Baxter's cash flows from operations and other sources of liquidity to meet its ongoing cash obligations and fund its investment program; loss of key employees or inability to identify and recruit new employees; future actions of regulatory bodies and other governmental authorities, including FDA, the Department of Justice, the SEC, the New York Attorney General and foreign regulatory agencies, including the continued delay in lifting the warning letter at Baxter's Ahmedabad facility; the outcome of pending or future litigation, including the opioid litigation and current and future ethylene oxide litigation or other claims; proposed regulatory changes of the U.S. Department of Health and Human Services in kidney health policy and reimbursement, which may substantially change the U.S. end-stage renal disease market and demand for the company's peritoneal dialysis products, necessitating significant multiyear capital expenditures, which are difficult to estimate in advance; failures with respect to compliance programs; future actions of third parties, including payers; U.S. healthcare reform and other global austerity measures; pricing, reimbursement, taxation and rebate policies of government agencies and private payers; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; fluctuations in foreign exchange and interest rates; the ability to enforce owned or in-licensed patents or the prevention or restriction of the manufacture, sale or use of products or technology affected by patents of third parties; global, trade and tax policies; any change in laws concerning the taxation of income (including current or future tax reform), including income earned outside the United States and potential taxes associated with the Base Erosion and Anti-Abuse Tax or the Build Back Better framework; actions taken by tax authorities in connection with ongoing tax audits; and other risks identified in Baxter's most recent filing on Form 10-K and other Securities and Exchange Commission filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements. Baxter | 2022 Investor Conference 73#3FRONT LINE CARE Empowering Clinicians to Help Enhance Outcomes for Patients Everywhere INTELLIGENT DIAGNOSTICS CONNECTED MONITORING RESPIRATORY HEALTH Baxter 2022 Investor Conference PREDICT PATIENT DETERIORATION II. LA IMPROVE CARE COORDINATION 3 G + MANAGE PATIENTS AT HOME 74#4Global Market Expected To Grow 5% -6% Through 2025 ~$7.8B ~$1.1B ~$2.6B ~$1.5B ~$2.6B 2022E CAGR 5% -6% Respiratory Health 6% -7% Connected Monitoring ~6% ligent Diagnostics 5% -6% Consumables & Other Products 3% -4% Baxter | 2022 Investor Conference ~$9.1B ~$1.4B ~$3.0B ~$1.8B -$2.9B 2025E Market Dynamics Opportunities Reducing deterioration and readmissions by building digital health platforms for earlier diagnosis and disease prevention Introducing connected ecosystem of devices to improve patient outcomes and clinical workflows Simplifying technologies to expand primary care capabilities, consistent with provider and patient preferences Challenges Accelerating remote engagement and digital health Global staffing shortages including key specialties Shifting sites of care from specialty to primary care ● 75#5Market-Leading Portfolio Connected Monitoring Help accelerate patient recovery by expanding the monitored population, generating insights and improving workflow efficiency Connex Spot Monitor Connex Vital Signs Monitor Respiratory Health Shifting care closer to home with innovative therapy and treatment solutions across care settings for chronic patients Monarch Airway Life2000 Clearance System Ventilation System Connex CS Software Baxter | 2022 Investor Conference Volara / Synclara OLE System Connected Monitoring 24% Respiratory Health 12% Intelligent Diagnostics 29% FY 2021 Revenue $1.1B Consumables & Other Products 35% Intelligent Diagnostics Help enable earlier diagnosis through better access, digital examination tools and improved care coordination PanOptic and MacroView Plus RetinaVue Care Delivery Model Thermometers & Probe Covers Consumables & Other Products Facilitating efficient patient exams to support clinical workflow and diagnosis ich Ally S SE BardyDX CAM Patch & Report Disposable Blood Pressure Cuffs 22 Women's Health 76#6#7#8#9#10#11